|
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 17938/22955 (78%)
Visitors : 7404222
Online Users : 119
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
https://ir.csmu.edu.tw:8080/ir/handle/310902500/20543
|
Title: | A Polymorphic −844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer |
Authors: | Sung, Wen-Wei Wang, Yao-Chen Cheng, Ya-Wen Lee, Ming-Ching Yeh, Kun-Tu Wang, Lee Wang, John Chen, Chih-Yi Lee, Huei |
Date: | 2011-09 |
Issue Date: | 2019-12-19T04:06:07Z (UTC)
|
Publisher: | Clinical Cancer Research |
ISSN: | 1078-0432 |
Abstract: | Purpose:Fas ligand (FasL) −844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL −844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL −844T/C polymorphism on the clinical outcome of non–small cell lung cancer (NSCLC) remains to be identified.
Experimental Design: A total of 385 adjacent normal lung tissues from patients with NSCLC were collected to determine FasL −844T/C polymorphism by PCR-based restriction fragment length polymorphism. FasL mRNA and protein expression in lung tumors were evaluated by real-time PCR and immunohistochemistry. The prognostic value of FasL −844T/C polymorphism on survival and relapse was determined by Kaplan–Meier analysis and Cox proportional hazards models.
Results: The FasL −844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors (P = 0.008). In addition, patients with the FasL −844CC genotype were more prone to tumor relapse than those with the FasL −844TT+TC genotype (62.1% vs. 37.9%, P = 0.001). Multivariate Cox regression analysis showed that patients with the FasL −844CC genotype had poorer survival in terms of overall survival (OS) and relapse-free survival (RFS) than those with the FasL −844TT+TC genotype (24.1 vs. 42.8 months for OS, HR = 1.455, P = 0.004; 15.4 vs. 31.4 months for RFS, HR = 1.710, P < 0.001).
Conclusions:FasL −844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group. Clin Cancer Res; 17(18); 5991–9. ©2011 AACR. |
URI: | https://ir.csmu.edu.tw:8080/ir/handle/310902500/20543 |
Relation: | Clinical Cancer Research, Volume 17, Issue 18 |
Appears in Collections: | [公共衛生學系暨碩士班] 期刊論文
|
Files in This Item:
File |
Description |
Size | Format | |
5991.full.pdf | | 405Kb | Adobe PDF | 220 | View/Open |
|
All items in CSMUIR are protected by copyright, with all rights reserved.
|